721 Views

Instructional Course

Instructional Course - Available with the Platinum and Silver packages or Individual Course Ticket

019IC - The Changing Face of Advanced Prostate Cancer 2022

Friday, May 13, 2022

4:00 PM – 6:00 PM

Location: Room 204

Instructional Course Director(s)

Judd W. Moul, MD, FACS

James H Semans MD Professor of Surgery
Duke University

Instructional Course Faculty(s)

Lawrence I. Karsh, MD, FACS

Director of Research
Attending Urologist and Director of Research Co Director Advanced Therapeutics Clinic
Alicia Morgans, MD, MPH

Faculty in Medicine
Harvard Medical School, Dana-Farber Cancer Institute

Learning Objectives:

Identify and treat a patient with new diagnosed M1 prostate cancer with androgen deprivation therapy (ADT) plus be able to offer additional therapies that extend survival.
Recognize high volume new M1 prostate cancer to be able to refer to a genitourinary (GU) medical oncologist for systemic chemotherapy.
Diagnose M0 metastatic CRPC and educate patients about using novel oral AR targeted therapeutics added to traditional ADT as a way to improve their patient's overall and radiographic progression-free survival.
Identify the differences between these AR targeted oral agents and to educate patients about side effects and toxicities.
Describe the latest phase III randomized control trial (RCT) results for new therapies in M1 CRPC.
Educate their patients on treatment options and work on a multi-disciplinary team caring for this disease state of far advanced prostate cancer.
Identify that advanced prostate cancer is a complex group of disease states with a rapidly changing therapeutic landscape and for providers and teams to embrace the multi-disciplinary nature of this care for our patients.
Identify the different treatment options and proper use and risks and side effects to better educate and counsel their patients.

This is an ongoing course on advanced prostate cancer at the annual AUA since 2012 and the changes over these 10 years have been nothing less than breathtaking! In the early years, it was all about metastatic castrate resistant prostate cancer (CRPC) with multiple new therapeutic advances starting in 2010 with novel immunotherapy, AR targeted therapies and bone-targeted agents. Later, the course expanded to cover hormone sensitive (HS) advanced disease due to the new data on systemic chemotherapy and AR-directed therapy extending survival in new M1 patients. In 2017, the topic of non-metastatic CRPC (M0 CRPC) was added due to emerging data on use of novel oral hormonal therapies. In 2019 before COVID, the course expanded information on HS new M1 disease with emerging data that four novel therapeutic strategies that all improved survival for men with new metastatic prostate cancer. Some may have argued that the value of the course for urologists was a stretch back in 2012 because of the belief, by some physicians, that metastatic CRPC should be managed only by medical oncologists. However, over the last few years; the course is even more relevant to practicing urologists as most M0 CRPC and virtually all new M1 HS patients are initially managed by urologists.

Using a case based and multi-disciplinary format, we will continue to push the boundaries of knowledge to urologists and their teams in covering this new toolbox of novel therapies. In addition, we will cover the latest advance in lutetium prostate-specific membrane antigen (PSMA) 617 (VISION and Thera-P trials), and the ACIS and the NGS update (ipatasertib). Finally, bi-specific and tri-specific antibodies are emerging, and will be covered in 2022.

It truly has been an honor and pleasure to present this constantly evolving course on advanced prostate cancer and celebrate the 10th anniversary of this ongoing educational exchange.